Literature DB >> 20130922

Enzymatic disease of the podocyte.

Andreas D Kistler1, Vasil Peev, Anna-Lena Forst, Shafic El Hindi, Mehmet M Altintas, Jochen Reiser.   

Abstract

Proteinuria is an early sign of kidney disease and has gained increasing attention over the past decade because of its close association with cardio-vascular and renal morbidity and mortality. Podocytes have emerged as the cell type that is critical in maintaining proper functioning of the kidney filter. A few genes have been identified that explain genetic glomerular failure and recent insights shed light on the pathogenesis of acquired proteinuric diseases. This review highlights the unique role of the cysteine protease cathepsin L as a regulatory rather than a digestive protease and its action on podocyte structure and function. We provide arguments why many glomerular diseases can be regarded as podocyte enzymatic disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130922      PMCID: PMC4109305          DOI: 10.1007/s00467-009-1425-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  39 in total

1.  Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).

Authors:  R J Hogg; R J Portman; D Milliner; K V Lemley; A Eddy; J Ingelfinger
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

2.  Human chronic kidney allograft rejection is accompanied by increased intraglomerular cathepsin B and L activity.

Authors:  L Paczek; J Pazik; M Teschner; R M Schaefer; W Rowinski; J Szmidt; M Lao; K Abgarowicz; L Gradowska; M Morzycka-Michalik; A Heidland
Journal:  Transpl Int       Date:  1994       Impact factor: 3.782

Review 3.  Regulating actin dynamics at membranes: a focus on dynamin.

Authors:  Dorothy A Schafer
Journal:  Traffic       Date:  2004-07       Impact factor: 6.215

4.  Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model.

Authors:  Dilys Chen; Barbara Jefferson; Scott J Harvey; Keqin Zheng; Cathy J Gartley; Robert M Jacobs; Paul S Thorner
Journal:  J Am Soc Nephrol       Date:  2003-03       Impact factor: 10.121

5.  Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes.

Authors:  Katsuhiko Asanuma; Isao Shirato; Kazumi Ishidoh; Eiki Kominami; Yasuhiko Tomino
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

6.  Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin.

Authors:  Jochen Reiser; Jun Oh; Isao Shirato; Katsuhiko Asanuma; Andreas Hug; Thomas M Mundel; Karen Honey; Kazumi Ishidoh; Eiki Kominami; Jordan A Kreidberg; Yasuhiko Tomino; Peter Mundel
Journal:  J Biol Chem       Date:  2004-06-14       Impact factor: 5.157

7.  Induction of B7-1 in podocytes is associated with nephrotic syndrome.

Authors:  Jochen Reiser; Gero von Gersdorff; Martin Loos; Jun Oh; Katsuhiko Asanuma; Laura Giardino; Maria Pia Rastaldi; Novella Calvaresi; Haruko Watanabe; Karin Schwarz; Christian Faul; Matthias Kretzler; Anne Davidson; Hikaru Sugimoto; Raghu Kalluri; Arlene H Sharpe; Jordan A Kreidberg; Peter Mundel
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 8.  Toward computer-based cleavage site prediction of cysteine endopeptidases.

Authors:  Tobias Lohmüller; Daniel Wenzler; Sascha Hagemann; Wolfgang Kiess; Christoph Peters; Thomas Dandekar; Thomas Reinheckel
Journal:  Biol Chem       Date:  2003-06       Impact factor: 3.915

9.  A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor.

Authors:  Brigitte Goulet; Amos Baruch; Nam-Sung Moon; Madeleine Poirier; Laurent L Sansregret; Ann Erickson; Matthew Bogyo; Alain Nepveu
Journal:  Mol Cell       Date:  2004-04-23       Impact factor: 17.970

Review 10.  Cell biology of the glomerular podocyte.

Authors:  Hermann Pavenstädt; Wilhelm Kriz; Matthias Kretzler
Journal:  Physiol Rev       Date:  2003-01       Impact factor: 37.312

View more
  7 in total

1.  N-Degradomic Analysis Reveals a Proteolytic Network Processing the Podocyte Cytoskeleton.

Authors:  Markus M Rinschen; Ann-Kathrin Hoppe; Florian Grahammer; Martin Kann; Linus A Völker; Eva-Maria Schurek; Julie Binz; Martin Höhne; Fatih Demir; Milena Malisic; Tobias B Huber; Christine Kurschat; Jayachandran N Kizhakkedathu; Bernhard Schermer; Pitter F Huesgen; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 10.121

Review 2.  Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.

Authors:  Judit Gordon; Jeffrey B Kopp
Journal:  Adv Chronic Kidney Dis       Date:  2011-07       Impact factor: 3.620

3.  Human Th17 cells produce a soluble mediator that increases podocyte motility via signaling pathways that mimic PAR-1 activation.

Authors:  Carl J May; Gavin I Welsh; Musleeha Chesor; Phillipa J Lait; Lauren P Schewitz-Bowers; Richard W J Lee; Moin A Saleem
Journal:  Am J Physiol Renal Physiol       Date:  2019-07-24

Review 4.  Nonimmunologic targets of immunosuppressive agents in podocytes.

Authors:  Tae-Hyun Yoo; Alessia Fornoni
Journal:  Kidney Res Clin Pract       Date:  2015-04-09

5.  Chronic cathepsin inhibition by E-64 in Dahl salt-sensitive rats.

Authors:  Gregory Blass; Vladislav Levchenko; Daria V Ilatovskaya; Alexander Staruschenko
Journal:  Physiol Rep       Date:  2016-09

6.  Alteration of histone H3K4 methylation in glomerular podocytes associated with proteinuria in patients with membranous nephropathy.

Authors:  Takayuki Fujino; Naoyuki Hasebe
Journal:  BMC Nephrol       Date:  2016-11-17       Impact factor: 2.388

7.  Baicalin improves podocyte injury in rats with diabetic nephropathy by inhibiting PI3K/Akt/mTOR signaling pathway.

Authors:  Yi Ou; Wenjuan Zhang; Shaopeng Chen; Haihua Deng
Journal:  Open Med (Wars)       Date:  2021-09-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.